Reprogramming regulatory T cell plasticity for cancer immunotherapy
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2026-09 · 1881 (4) · 189605
DOI: 10.1016/j.bbcan.2026.189605 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2026-09. Verfasst von Mark E Issa und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Division of Pathology, Karolinska Institute, Huddinge, Stockholm, Sweden. Electronic address: mark.issa@ki.se. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, Neoplasms, Immunotherapy, Cell Plasticity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Regulatory T cells (Tregs) maintain immune homeostasis by suppressing excessive immune responses. In the context of cancer, Tregs are abundantly recruited to inhibit immunity against tumoral cells, facilitate immune evasion, and promote tumor progression. While Treg depletion strategies have repeatedly failed in the clinic due to severe autoimmune side effects, lack of specificity, and rapid compensatory recruitment, a critical unmet need remains for safer and more effective approaches. Emerging evidence highlights the remarkable plasticity of Tregs, allowing them to adopt an inflammatory phenotype in response to tumor-associated cytokines. Thus, leveraging this plasticity, rather than attempting broad depletion, may represent a superior anticancer strategy. This plasticity is marked by the expression of transcription factors like T-bet (Th1-like) and RORγt (Th17-like), the production of pro-inflammatory cytokines such as IFN-γ and IL-17, and even the acquisition of differential energetic preferences pertaining to glucose or glutamine. These changes can weaken Treg suppressive functions or paradoxically enhance inflammation in the tumor microenvironment, thereby creating a complex interplay between immune suppression and anti-tumor effector activity. Understanding the molecular cues driving Treg plasticity is therefore critical for designing novel therapies that shift Tregs toward an effector-like state, ultimately enhancing anti-tumor immunity and improving the efficacy of current immunotherapies. This review offers a fresh perspective on how Treg plasticity can be therapeutically harnessed to overcome the persistent limitations of conventional Treg-targeted approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Division of Pathology, Karolinska Institute, Huddinge, Stockholm, Sweden. Electronic address: mark.issa@ki.se.
- Department of Laboratory Medicine, Division of Pathology, Karolinska Institute, Huddinge, Stockholm, Sweden; Department of Medical Microbiology & Immunology, University of Alberta, Edmonton, AB, Canada. Electronic addre…
- Department of Dermatology, Center for Cancer Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Zitieren
APA
Issa, M. E., Schcolnik-Cabrera, A., & Monetta, R. (2026). Reprogramming regulatory T cell plasticity for cancer immunotherapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1881(4), 189605. https://doi.org/10.1016/j.bbcan.2026.189605
Vancouver
Issa ME, Schcolnik-Cabrera A, Monetta R. Reprogramming regulatory T cell plasticity for cancer immunotherapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2026;1881(4):189605. doi:10.1016/j.bbcan.2026.189605
BibTeX
@article{Issa2026,
author = {Issa, Mark E and Schcolnik-Cabrera, Alejandro and Monetta, Rosanna},
title = {Reprogramming regulatory T cell plasticity for cancer immunotherapy},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2026},
volume = {1881},
number = {4},
pages = {189605},
doi = {10.1016/j.bbcan.2026.189605}
}
EUVIMED